OBJECTIVE: The diagnosis of leptomeningeal metastases (LM) is based on clinical symptoms, magnetic resonance imaging (MRI) of brain and spine and cytological analysis of cerebrospinal fluid (CSF). The clinical picture of LM is highly variable and both cytological CSF analysis and contrast-enhanced MRI are limited in sensitivity. More sensitive tools are needed to diagnose LM. We measured a profile of proteins involved in adhesion and inflammation in the CSF of LM and control patients and determined their potential diagnostic value for LM. PATIENTS AND METHODS: Using Multiplex Immuno-Assay (MIA), the CSF concentrations of nine soluble adhesion molecules, cyto- and chemokines were measured in patients with cytologically proven LM (n = 57) and control patients with a systemic malignancy (n = 20), aseptic/viral meningitis (n = 11) or other (non-)neurological diseases (n = 19). RESULTS: We found high CSF levels of soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), soluble Intercellular Adhesion Molecule-1 (sICAM-1), Interleukin-8 (IL-8), Pulmonary and Activation Regulated Chemokine (PARC), Interleukin-18 (IL-18) and Interferon-gamma inducible protein (IP-10) in patients with LM. The CSF protein profile in LM patients differed significantly from the profile found in control patients. Multivariate logistic regression and ROC analysis showed that the MIA-measured CSF protein profile has an additive discriminating value for LM above standard CSF parameters. A combination of total protein, glucose, IL-8, PARC and IP-10 CSF levels proved to be most discriminative between LM and non-LM patients. CONCLUSION: Our results warrant a prospective study to determine whether a CSF protein profile, including IL-8, PARC and IP-10 has diagnostic value compared with CSF cytology, the golden standard for LM.
OBJECTIVE: The diagnosis of leptomeningeal metastases (LM) is based on clinical symptoms, magnetic resonance imaging (MRI) of brain and spine and cytological analysis of cerebrospinal fluid (CSF). The clinical picture of LM is highly variable and both cytological CSF analysis and contrast-enhanced MRI are limited in sensitivity. More sensitive tools are needed to diagnose LM. We measured a profile of proteins involved in adhesion and inflammation in the CSF of LM and control patients and determined their potential diagnostic value for LM. PATIENTS AND METHODS: Using Multiplex Immuno-Assay (MIA), the CSF concentrations of nine soluble adhesion molecules, cyto- and chemokines were measured in patients with cytologically proven LM (n = 57) and control patients with a systemic malignancy (n = 20), aseptic/viral meningitis (n = 11) or other (non-)neurological diseases (n = 19). RESULTS: We found high CSF levels of soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), soluble Intercellular Adhesion Molecule-1 (sICAM-1), Interleukin-8 (IL-8), Pulmonary and Activation Regulated Chemokine (PARC), Interleukin-18 (IL-18) and Interferon-gamma inducible protein (IP-10) in patients with LM. The CSF protein profile in LM patients differed significantly from the profile found in control patients. Multivariate logistic regression and ROC analysis showed that the MIA-measured CSF protein profile has an additive discriminating value for LM above standard CSF parameters. A combination of total protein, glucose, IL-8, PARC and IP-10 CSF levels proved to be most discriminative between LM and non-LM patients. CONCLUSION: Our results warrant a prospective study to determine whether a CSF protein profile, including IL-8, PARC and IP-10 has diagnostic value compared with CSF cytology, the golden standard for LM.
Authors: Wilco de Jager; Berent J Prakken; Johannes W J Bijlsma; Wietse Kuis; Ger T Rijkers Journal: J Immunol Methods Date: 2005-05 Impact factor: 2.303
Authors: K Hieshima; T Imai; M Baba; K Shoudai; K Ishizuka; T Nakagawa; J Tsuruta; M Takeya; Y Sakaki; K Takatsuki; R Miura; G Opdenakker; J Van Damme; O Yoshie; H Nomiyama Journal: J Immunol Date: 1997-08-01 Impact factor: 5.422
Authors: O M Koper; J Kamińska; K Sawicki; J Reszeć; R Rutkowski; M Jadeszko; Z Mariak; V Dymicka-Piekarska; H Kemona Journal: Ir J Med Sci Date: 2017-10-30 Impact factor: 1.568
Authors: Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain Journal: J Neurooncol Date: 2014-01-28 Impact factor: 4.130
Authors: Lakshmi Nayak; Martin Fleisher; Rita Gonzalez-Espinoza; Oscar Lin; Katherine Panageas; Anne Reiner; Chhui-Mei Liu; Lisa M Deangelis; Antonio Omuro Journal: Neurology Date: 2013-04-03 Impact factor: 9.910
Authors: Bojana Milojkovic Kerklaan; Dick Pluim; Mijke Bol; Ingrid Hofland; Johan Westerga; Harm van Tinteren; Jos H Beijnen; Willem Boogerd; Jan H M Schellens; Dieta Brandsma Journal: Neuro Oncol Date: 2015-11-12 Impact factor: 12.300